Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Difelikefalin for Pruritus in Advanced CKD
NCT05356403Phase 3Terminated
- Sponsor
- Cara Therapeutics, Inc.
- Start
- Aug 2022
- Primary completion
- Feb 2024
- Modality
- Peptides, Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of difelikefalin in pruritus, sponsored by Cara Therapeutics, Inc.. Started Aug 2022; status: terminated.
02
Drugs
difelikefalin
03
Conditions
pruritus
Beyond the preview
Go deeper on NCT05356403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05356403.